Switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 24 weeks in a Montreal cohort.

Abstract

Sorry, we couldn't extract an abstract for this paper.
DOI: 10.1097/QAI.0b013e3181aa1398

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.